IC
MLTX icon

Ikarian Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Ikarian Capital’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-435,839
Closed -$3.12M – 205
2025
Q3 		$3.12M Buy
+435,839
New +$22.7M 0.32% 80

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Ikarian Capital's MLTX Position: Q4 2025 in Review

Ikarian Capital sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 435,839 shares — an estimated $3.12M sold.

Ikarian Capital first reported a position in MLTX in Q3 2025 and held it in 1 quarter. The position peaked at $3.12M in Q3 2025. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

  • Ikarian Capital reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Ikarian Capital sold 435,839 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $3.12M.
  • Ikarian Capital first reported a position in MoonLake Immunotherapeutics in Q3 2025 and held it in 1 quarter.
  • Ikarian Capital's MoonLake Immunotherapeutics position peaked at $3.12M in Q3 2025.
  • 130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on Ikarian Capital's 13F filing for Q4 2025, filed 18 Feb 2026.